The epithelial-to-mesenchymal transition (EMT) is a cellular process that functions during embryonic development and tissue regeneration, thought to be aberrantly activated in epithelial-derived cancer and has an important role in the process of metastasis. The transforming growth factor (TGF)-β signaling pathway is a key inducer of EMT and we have elucidated a posttranscriptional mechanism by which TGFβ modulates expression of select transcripts via the RNA-binding protein hnRNP E1 during EMT. One such transcript inhibin βA is a member of the TGFβ superfamily. Here, we show by polysome profiling that inhibin βA is translationally regulated by TGFβ via hnRNP E1. TGFβ treatment or knockdown of hnRNP E1 relieves silencing of the inhibin βA transcript, resulting in increased protein expression and secreted levels of the inhibin βA homodimer, activin A. Our data indicate that the translational upregulation of inhibin βA enhances the migration and invasion of cells that have undergone an EMT and promotes cancer progression in vivo.
INTRODUCTION
The epithelial-to-mesenchymal transition (EMT) is a cellular process that is thought to have a key role in the metastatic progression of epithelial-derived cancers. 1 This transition is associated with reorganization of the actin cytoskeleton and microtubule network, a loss of cell-cell contacts and an increase in the migratory and invasive capabilities of transitioned cells. 2 A key inducer of EMT is the transforming growth factor (TGF)-β signaling pathway, which signals through the type II receptor TβRII and the type I receptor Alk5, activating the canonical Smad2/3 pathway and non-canonical pathways including AKT, ERK and p38 MAPK. 3 The induction of EMT by TGFβ is associated with increased migration, invasion and acquisition of cancer stem cell properties that are linked to metastatic potential. 2, 4 This process is regulated not only at the transcriptional level through factors such as Zeb1/2, Snail and Slug, but also posttranscriptionally. 5 Our laboratory has delineated a mechanism through which EMT is posttranscriptionally regulated by the RNA-binding protein hnRNP E1. 6, 7 We have shown that hnRNP E1 binds to select mRNAs and silences their translation in the absence of TGFβ signaling. In a global unbiased approach to identify transcripts silenced by this mechanism, using polysome profiling of normal murine mammary gland (NMuMG) epithelial cells, inhibin βA was identified as translationally regulated by TGFβ. 8 Inhibin βA forms the homodimer activin A, which is a member of the TGFβ superfamily. This ligand functions in diverse processes and was originally identified for its role in reproduction through the modulation of follicle stimulating hormone levels. 9 Activin A also functions during embryogenesis and in several differentiation processes including hematopoiesis and osteogenesis. [10] [11] [12] Similar to TGFβ, activin A signals through the Smad2/3 pathway albeit through different receptors. Activin A interacts with the type II activin receptors, ActRIIA and ActRIIB, leading to the recruitment and activation of the type I receptor Alk4 and subsequent phosphorylation of Smad2/3. Smad4 associates with activated Smad2/3 forming a complex which translocates to the nucleus and activates transcription. 13 Similar to the role of TGFβ in tumorigenesis, activin A has been shown to exert both tumor-suppressing and -promoting effects. Activin A is reported to inhibit cancer cell proliferation in certain models and to promote cell migration, invasion and acquisition of cancer stem cell traits in others. [14] [15] [16] In vivo, increased inhibin βA expression is observed in cancer tissue compared with normal tissue in several cancers, including breast. [17] [18] [19] Furthermore, inhibin βA is overexpressed in cancers with a propensity to metastasize with increased levels of secreted activin A observed in cancer patients with metastasis of the bone, [20] [21] [22] indicating a cancer-promoting effect of activin A in advanced stages of the disease.
In this study, we show that TGFβ treatment or knockdown of hnRNP E1 relieves silencing of the inhibin βA transcript, resulting in increased protein levels and secreted levels of the inhibin βA homodimer, activin A. Activin A treatment enhanced the invasion of TGFβ-treated NMuMG cells, whereas inhibin βA silencing inhibited NMuMG cell migration and invasion in vitro. In a xenograft mouse model, inhibin βA knockdown attenuated the metastatic progression of hnRNP E1-silenced cells. Thus, inhibin βA translational upregulation induced by TGFβ or hnRNP E1 knockdown appears to promote the migratory and invasive phenotype observed in these cells.
RESULTS
Inhibin βA is translationally regulated by TGFβ in a hnRNP E1-dependent manner We have previously identified inhibin βA (InhβA) as a candidate target of the RNA binding protein hnRNP E1 through combined polysome profiling and Affymetrix array (Figure 1a ). To validate these findings, transcript and protein expression levels were initially assessed in NMuMG cells, hnRNP E1 knockdown cells (E1KD) and also in the KiWT cell line (E1KD cells that express the hnRNP E1 open reading frame, not targeted by shRNA-mediated silencing). No change in inhibin βA mRNA was observed following TGFβ treatment in NMuMG cells, indicating that the inhibin βA transcript is not transcriptionally regulated by TGFβ (Figure 1b ). In addition, no significant change in transcript was observed between the NMuMG, E1KD and KiWT cell lines (Figure 1b) . In contrast, inhibin βA protein levels were significantly increased within 3 h of TGFβ treatment in NMuMG cells and were twofold higher in E1KD cells in the absence of TGFβ (Figure 1c ). An antibody that detects the precursor form of inhibin βA, which has a molecular weight of 47kDa, was used in this study. The lower band in inhibin βA immunoblots corresponds to 47kDa and the upper band is believed to be the mono-glycosylated form of this precursor, which has been described previously. 23 The regulation of inhibin βA by hnRNP E1 was also assessed in the human mammary epithelial HMLE cell line which consists of a mixed population of epithelial cells (CD44-low/CD24-high sorted cells) and a stably transitioned mesenchymal subpopulation (CD44-high/CD24-low sorted cells) (Supplementary Figure S1A) . We hypothesized that inhibin βA would be translationally upregulated following TGFβ treatment in the epithelial subpopulation. Consistent with our data using NMuMG cells, we observed no change in inhibin βA transcript levels ( Figure 1d ) and significantly higher protein levels in HMLE epithelial cells (Figure 1e ) upon TGFβ treatment. Interestingly, higher levels of inhibin βA protein were observed in the mesenchymal subpopulation ( Figure 1e ). Next, we assessed the effect of hnRNP E1 knockdown on inhibin βA expression in the HMLE epithelial subpopulation. Similar to hnRNP E1 knockdown in NMuMG cells, silencing of hnRNP E1 led to an increase in inhibin βA protein levels, whereas no change in transcript level was observed (Figure 1f) .
We utilized polysome profiling to confirm that increased inhibin βA protein levels were due to translational activation ( Figure 2 ). Global translation levels were only modestly affected by either TGFβ treatment or hnRNP E1 knockdown in NMuMG cells (Figure 2a ) and the HMLE epithelial subpopulation (Figure 2b) as assessed by quantitation of RNA concentration (abs 254nm) across polysome fractions. In contrast, polysomal analysis in the mesenchymal HMLE subpopulation indicated that the increase in inhibin βA protein levels observed in this subpopulation was due to an increase in global translation levels when compared with epithelial HMLE cells (Supplementary Figure S1B) .
Upon transcript-selective analysis, we observed a shift of the inhibin βA transcript from the monosomal to polysomal fractions upon TGFβ treatment of both NMuMG (Figure 2c ) and HMLE epithelial (Figure 2d ) cells, indicative of active translation. Inhibin βA transcript was present in denser polysomal fractions, irrespective of TGFβ treatment in hnRNP E1-silenced NMuMG cells (E1KD; Figure 2c ) and hnRNP E1-silenced HMLE epithelial cells (Epi E1KD; Figure 2d ). Additionally, the rescue of hnRNP E1 silencing in the E1KD cells by expression of non-targeted human hnRNP E1 resulted in a shift of the inhibin βA transcript back to the monosomal fractions (KiWT; Figure 2c ). Further, RNA immunoprecipitation analysis using anti-hnRNP E1 antibody demonstrates that in both NMuMG ( Figure 2e ) and HMLE ( Figure 2f ) cells, inhibin βA transcript associates with hnRNP E1 and this interaction is lost upon TGFβ treatment, indicating that direct interaction between hnRNP E1 and the inhibin βA transcript is required for translational regulation. Overall, these data indicate that the induction of inhibin βA following TGFβ treatment is mediated by hnRNP E1 which functions as a translational silencer in our model. To determine whether the secreted activin A was active, we first established in serum-starved NMuMG cells that recombinant activin A is capable of inducing phospho-Smad2/3 ( Figure 3c ) and recombinant activin A treatment was also capable of further increasing phospho-Smad2/3 levels induced in TGFβ-treated cells (Figure 3c ). Induction of the non-canonical MAPK pathway, as determined by ERK1/2 phosphorylation, was also observed in single and combination treatments, whereas the Akt pathway was not significantly activated ( Figure 3c ). Next, the activity of E1KD CM, which contains significantly higher levels of activin A compared with NMuMG cells, was characterized. As depicted in Figure 3d , phospho-Smad2 levels were induced in serum-starved NMuMG cells upon addition of E1KD CM compared with NMuMG CM and with Dulbecco's modified Eagle's medium (DMEM) control. Recombinant activin A was used as a positive control in this experiment.
Next, the contribution of activin A to Smad2/3 activation was assessed. We silenced inhibin βA in E1KD cells resulting in a reduction in secreted levels of activin A ( Figure 3e ) and an attenuation of Smad2/3 activation when NMuMG cells were treated with CM from inhibin βA KD cells compared with E1KD CM (Figure 3f ). We also immunodepleted activin A from E1KD CM (Supplementary Figure S2B) and similarly observed a reduction in Smad2 activation compared with IgG control CM (Figure 3g ). These data indicate that the activin A ligand significantly contributes to Smad2/3 activation induced by E1KD CM.
Translational upregulation of inhibin βA promotes cell migration and invasion following TGFβ treatment and hnRNP E1 silencing We wished to elucidate the functional significance of inhibin βA upregulation in response to TGFβ treatment. We hypothesized that inhibin βA may either promote EMT or function in promoting some aspect of the mesenchymal phenotype, such as migration or invasion. Previous studies have reported a lack of EMT induction in activin A-treated NMuMG cells owing to limited receptor levels, therefore, we initially characterized the expression of activin receptors in NMuMG cells, in addition to the effect of activin A and combined activin A/TGFβ treatment on EMT. The type II receptor ActRIIA and the type I receptor Alk4, which form heteromeric complexes in NMuMG cells, 24 were detected in cell lysates with higher levels of the type II receptor observed in E1KD cells. An increase in the type I receptor Alk4 was observed within 3 h of TGFβ treatment, which returned to basal levels within 24 h of treatment. In contrast, expression of the type II receptor did not change upon TGFβ treatment (Supplementary Figures S3A and B) .
Morphologically, the transition to a more spindle-shaped, fibroblast-like cell that occurs during TGFβ-induced EMT was not observed following activin A exposure (Supplementary Figure  S3C) . A slight loss of the epithelial marker E-cadherin at the cell membrane was detected in activin A-treated cells, however, no microtubule reorganization was observed as determined by α-tubulin immunofluorescence (Figure 4a ). In contrast, TGFβ and combined TGFβ/activin A treatment resulted in complete loss of E-cadherin at the cell membrane and reorganization of the microtubule network. shRNA-mediated silencing of inhibin βA had a modest effect on TGFβ-induced EMT, as determine by the partial loss of E-cadherin at the cell membrane following TGFβ treatment compared with control TGFβ-treated cells (Figure 4a ). Finally, induction of the EMT-associated transcription factors Zeb1/2, the Smad target GADD45b and the mesenchymal marker N-cadherin was not observed in activin A-treated cells compared with TGFβ-treated cells (Supplementary Figures S3D and E) . These data indicate that exogenous activin A, or TGFβ-induced inhibin βA, is not sufficient to induce an EMT in NMuMG cells.
To investigate whether activin A promotes invasion and migration in control and TGFβ-treated cells, we performed wound-healing and invasion assays. The results demonstrate that treatment of NMuMG cells with either TGFβ or activin A promoted cell migration (Figure 4b ) and invasion (Figure 4c ). Combined treatment of activin A and TGFβ did not significantly alter cell migration, but did enhance cell invasion (Figures 4b and c) . Furthermore, migration and invasion were significantly attenuated when inhibin βA was silenced using two different shRNAs in NMuMG cells (Figure 4d and Supplementary Figure S4) . Additionally, in the spontaneously arising mesenchymal subpopulation of HMLE cells, which exhibits enhanced invasiveness compared with their epithelial counterparts (Figure 4g ), silencing of inhibin βA attenuated migration and invasion (Figures 4f and g ).
Our results demonstrate that knockdown of hnRNP E1 in both NMuMG (E1KD) and HMLE (Epi E1KD) cells results in the induction of inhibin βA (Figure 1 ) with concomitant altered cell morphology, loss of cell-cell contacts and increased motility and invasiveness (Figures 4e and h) . To determine the contribution of inhibin βA induction to these cellular phenotypes, silencing of inhibin βA in both EIKD (Figure 4e ) and Epi E1KD (Figure 4h ) cells was performed resulting in a significant reduction in invasion. These data suggest that enhanced invasiveness observed following TGFβ treatment or hnRNP E1 knockdown is in part due to an upregulation of inhibin βA.
To establish the relative contribution of inhibin βA to the invasive and metastatic phenotype in vivo, we initially assessed tumor formation and lung colonization using control and inhibin βA-silenced E1KD cells (Figure 3e ). E1KD cells formed primary tumors when injected into the mammary fat pad of NOD/SCID mice and formed lung colonies when tail vein injections were performed, albeit with low efficiency (data not shown). Owing to the low number of metastatic outgrowths observed in E1KD-injected animals, we generated a more aggressive form of E1KD cells using a process of in vivo selection. Briefly, lung metastases generated from mammary fat pad injection of E1KD cells were isolated and cells from these metastases were cultured in selective media generating the L1P cell line, the L2P cell line was isolated from the lungs metastases of L1P-injected mice.
We hypothesized that if inhibin βA is necessary for the invasive phenotype of hnRNP E1 cells, silencing of inhibin βA in these serially selected cells that aggressively metastasize to lung would attenuate this invasive phenotype. As shown in Figure 5A , in vivo selected cells demonstrate enhanced invasive ability, are still silenced for hnRNP E1 and exhibit increased levels of inhibin βA compared with parental NMuMG cells.
In vitro, the increased migratory and invasive ability observed in L2P cells compared with E1KD cells was attenuated by inhibin βA silencing (L2P InhβA KD cells; Figure 5B ). Consistent with these findings, tail vein injection of L1P and L2P cells resulted in an increase in lung colonization in NOD/SCID mice compared with E1KD cells, and silencing of inhibin βA in L2P cells (L2P InhβA KD) using two different shRNAs attenuated lung colonization ( Figure 5C ). Immunohistochemical analysis of the epithelial marker E-cadherin and the mesenchymal marker Vimentin in metastatic outgrowths revealed expression of both markers indicative of a partial reversal of the EMT phenotype, which has been described previously in metastases. 25 The proliferative marker Ki67 was also analyzed with an increase in nuclear ki67 staining observed in L2P lung colonies compared with L1P colonies (Figure 5D ). Inhibin βA knockdown also attenuated tumor growth in our model as inhibin βA-silenced L1P cells (L1P InhβA KD) formed mammary fat pad tumors that were significantly smaller in size than control L1P tumors ( Figure 5E ).
Inhibin βA is upregulated in breast cancer and is associated with poor prognosis To correlate our findings with human breast cancer data, we assessed inhibin βA protein expression by immunohistochemistry in human breast tissue microarrays (TMAs) obtained from the Biorepository and Tissue Analysis core of MUSC (Supplementary  Table S2 ). Inhibin βA expression was localized predominantly to the cytoplasm of cells and was detected in mammary gland hnRNP E1 translationally regulates inhibin βAepithelial cells of normal tissue biopsies ( Figure 6A) . A significant increase in inhibin βA expression was observed in pre-malignant and tumor tissue compared with normal breast tissue ( Figure 6A) . Furthermore, when tumor biopsies were divided into two groups based on inhibin βA expression levels, a significant correlation between overall survival and inhibin βA expression was observed, with high inhibin βA expression associated with poor prognosis ( Figure 6B ; P = 0.023). No correlation between inhibin βA expression and tumor size or lymph node involvement was observed, however, high expression of inhibin βA was observed in 67% of metastatic lymph node biopsies ( Figure 6C ).
DISCUSSION
During TGFβ-induced EMT, the transition to a mesenchymal phenotype requires not only TGFβ-induced transcriptional regulation, through factors such as Zeb1/2, but also coordinated posttranscriptional regulation, via microRNAs and RNA-binding proteins, such as hnRNP E1. 5, 6 We have shown previously that hnRNP E1 is a key regulator of TGFβ-induced EMT. Silencing of this protein induces a transition of epithelial cells to a mesenchymal phenotype, resulting in enhanced migration, invasion and tumorigenesis. 6, 7 Here, we show that the inhibin βA transcript is translationally regulated by hnRNP E1 during TGFβ-induced EMT and contributes to the enhanced migration and invasion observed in transitioned cells.
Transcriptional regulation of the inhibin βA gene has been reported previously, with IL-1β, NFκB and MAPK signaling being linked to this regulation. 26, 27 To our knowledge, this is the first study demonstrating translational regulation of inhibin βA. An upregulation of inhibin βA protein occurs within 3 h of TGFβ treatment with an increase in secreted levels of the inhibin βA homodimer, activin A, observed within 24 h. Polysome profiling in NMuMG and HMLE cells confirmed translational activation of inhibin βA following TGFβ treatment or hnRNP E1 silencing. Furthermore, the enhancement of inhibin βA translation coincided with the release of the RNA binding protein from the transcript. This finding is consistent with our previous data which show loss of interaction of hnRNP E1 with ILEI and Dab2 mRNA following TGFβ treatment, two transcripts that are translationally regulated by this RNA-binding protein. 6 Further work is required to characterize the cis-element in the inhibin βA transcript through which hnRNP E1 interacts.
The functional significance of inhibin βA upregulation was assessed in NMuMG and HMLE cell lines. Activin A alone was not capable of inducing an EMT nor did this ligand appear to enhance the transition induced by TGFβ. These findings are consistent with previous studies which report no induction of EMT in NMuMG cells treated with activin A. 24, 28 This lack of induction is thought to be due to limited receptor levels and weak Smad activation, as expression of constitutively active ALK4 induces an EMT. 28 The ability of activin A signaling to alter cell migration and invasion but not EMT in our model may be due to the degree or duration of Smad2/3 activation. TGFβ maintained Smad2 activation throughout a 24 h time course, whereas activin A induced phosphorylated Smad2 to a lesser degree and this activation was lost 12 h following treatment. During embryonic development, Smad2 binds to and activates transcription of target gene subsets in a dose-dependent manner, 29 it is possible that a certain threshold of Smad activation is also required in our model to promote transcription of genes necessary for EMT induction.
The ability of activin A signaling to alter cell migration and invasion may also be due to non-canonical pathways, such as the MAPK pathway. Induction of the MAPK pathway has been linked previously to enhanced cell migration and invasion in TGFβ-treated epithelial cells, 30 and we observed sustained ERK1/2 phosphorylation in activin A-treated cells comparable with levels observed in TGFβ-treated cells (Supplementary Figure 3F) . Thus, non-canonical activin signaling may have an important role in the invasive phenotype.
In vivo, inhibin βA appears to promote cancer progression as silencing of inhibin βA in our model resulted in an attenuation of xenograft cancer progression ( Figures 5C and E) . Consistent with these findings, analysis of secreted activin A levels from the 4T1 progression model revealed significantly elevated levels of activin A in the metastatic 4T1 cell line compared with non-invasive 67NR cells and invasive but non-metastatic 4T07 cells (Supplementary Figure S5) . These data are consistent with our immunohistochemical analysis of inhibin βA levels in human breast tissue in which inhibin βA protein levels were upregulated in tumor compared with normal breast tissue. In addition, inhibin βA expression was significantly higher in premalignant biopsies, indicating that upregulation of inhibin βA is an early event in cancer progression. We found that high levels of inhibin βA in tumor specimens were associated with poor prognosis. This is consistent with previous studies which report an association between inhibin βA protein levels and overall survival in patients with lung and gastric cancer. 19, 31 In summary, we have shown that inhibin βA is translationally repressed by the RNA-binding protein hnRNP E1. During TGFβ-induced EMT, we observe a loss of interaction between hnRNP E1 and the inhibin βA transcript, concomitant with an upregulation of inhibin βA translation, which contributes to the enhanced invasive phenotype observed in transitioned cells. Future research will be necessary to characterize this regulatory mechanism in processes, such as development, inflammation and immunity, in which inhibin βA functions.
MATERIALS AND METHODS

Cell lines and treatments
NMuMG cells, obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA), and the 4T1 progression model, acquired from Dr William Schiemann, were cultured in DMEM high glucose supplemented with 10% fetal bovine serum and 1% antibiotic/antimycotic solution (penicillin G, streptomycin, amphotericin B). HMLE cells were obtained from Dr Sendurai Mani and cultured in DMEM:F12 supplemented with 5% calf serum, 0.5 μg/ml hydrocortisone, 10 μg/ml insulin, 20 ng/ml epidermal growth factor and 1% antibiotic/antimycotic. The HMLE subpopulations were initially isolated as described previously 4, 32 and subsequently fluorescence-assisted cell sorted using CD44 and CD24 antibodies (see Supplementary methods). All cells were cultured in a 37°C, 5% CO 2 incubator. Recombinant activin A was purchased from R&D systems (Minneapolis, MN, USA). TGFβ2 was a generous gift from Genzyme Corporation (Cambridge, MA, USA). 
Polysome profiling
Cytosolic cell extracts were layered onto sucrose gradients (10-50%) and centrifuged at 35 000 r.p.m. in a SW40Ti rotor for 3 h at 4°C. Fractions were collected and RNA was isolated using Trizol as per manufacturer's instructions (Life Technologies, Carlsbad, CA, USA). Monosomal and polysomal fractions were determined by analysis of 18 S and 28 S rRNA levels using denaturing agarose gel electrophoresis (see Supplementary methods). The levels of inhibin βA transcript across fractions were assessed by semi-quantitative PCR (see Supplementary methods).
Migration assay
Migration was assessed using the CytoSelect 24-Well Wound Healing Assay (Cell Biolabs, San Diego, CA, USA). Wound-healing inserts were removed from confluent monolayers and cells were fixed and stained at 0, 12 h or 24 h.
Wound area was determined using ImageJ software (NIH, Bethesda, MO, USA) to calculate % wound recovery compared with control or 0 h samples.
Two-dimensional invasion assay
Invasion across a basement membrane was performed using BD BioCoat Matrigel Invasion Chambers (BD Biosciences, San Jose, CA, USA). Briefly, a volume of 0.5 ml cell suspension at a density of 2 × 10 5 cells per ml in serumfree DMEM was added to invasion chambers, a volume of 750 μl DMEM supplemented with 10% fetal bovine serum was added to wells that contained invasion chambers. After 16-22 h, invasive cells located on the underside of chambers were stained (cell stain solution, Cell Biolabs), imaged and quantitated by measuring absorbance at 570 nm of extracted cell stain following incubation of inserts in 400 μl extraction solution (Cell Biolabs) for 10 min. 
